ArticleMolecular and clinical oncology2014
Advances in intravesical therapy for the treatment of non-muscle invasive bladder cancer (Review).
Article in Molecular and clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Hybrid Nanoparticles as an Efficient Porphyrin Delivery System for Cancer Cells to Enhance Photodynamic Therapy.Frontiers in bioengineering and biotechnology · 2021Article
- Protein kinase D inhibitor CRT0066101 suppresses bladder cancer growth in vitro and xenografts via blockade of the cell cycle at G2/M.Cellular and molecular life sciences : CMLS · 2018Article
- The role of LIM and SH3 protein-1 in bladder cancer metastasis.Oncology letters · 2017Article
- Oxymatrine inhibits proliferation of human bladder cancer T24 cells by inducing apoptosis and cell cycle arrest.Oncology letters · 2017Article
- Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics.Scientific reports · 2017Article
- Down-regulation of lncRNA CASC2 promotes cell proliferation and metastasis of bladder cancer by activation of the Wnt/β-catenin signaling pathway.Oncotarget · 2017Article
- A Hydrogel-Based Epirubicin Delivery System for Intravesical Chemotherapy.Molecules (Basel, Switzerland) · 2016Article
- Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach.International journal of oncology · 2016Article
- Review
- Intravesical liposome drug delivery and IC/BPS.Translational andrology and urology · 2015Review
- Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know?Bladder cancer (Amsterdam, Netherlands) · 2015Review
- Immunotherapy and Radiation - A New Combined Treatment Approach for Bladder Cancer?Bladder cancer (Amsterdam, Netherlands) · 2015Review
- Association detection between genetic variants in the microRNA binding sites of toll-like receptors signaling pathway genes and bladder cancer susceptibility.International journal of clinical and experimental pathology · 2014Article
- Association between polymorphisms in the integrin gene predicted microRNA binding sites and bladder cancer risk.International journal of clinical and experimental medicine · 2014Article
- Desloratadine, a Novel Antigrowth Reagent for Bladder Cancer.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The knowledge of tumor biology and the biomechanical properties of the urothelium have led to significant advances in the development of intravesical therapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Targeted therapy improves the efficacy and decreases the side effects of antineoplastic agents. Nanoparticles that target antitumor agents to the urothelial cells have allowed for improved delivery of these agents to tumor cells. Gene therapy is another strategy that has allowed for a targeted induction of an antitumor response. Finally, engineering of the bacillus Calmette-Guérin (BCG) vaccine aimed to minimize the potential side effects associated with this treatment. These novel approaches hold promise for decreasing the rate of progression and recurrence of NMIBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.